Related references
Note: Only part of the references are listed.Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan
Y. Endo et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2020)
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2019)
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial
Jeremy Sokolove et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
L. Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis
Maurizio Cutolo et al.
AUTOIMMUNITY REVIEWS (2013)
Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes
J. Bathon et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
Dafna D. Gladman et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
J. S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Psoriatic arthritis: from pathogenesis to therapy
Oliver FitzGerald et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Classification criteria for psoriatic arthritis - Development of new criteria from a large international study
William Taylor et al.
ARTHRITIS AND RHEUMATISM (2006)
Dactylitis in psoriatic arthritis: a marker for disease severity?
JE Brockbank et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Share Paper
